Dr. Leen Kawas is a renowned leader in the biopharmaceuticals industry, currently acting as President and CEO of M3 Biotechnology. They specialize in the development of treatments for neurological diseases such as Parkinson’s and Alzheimer’s.
Dr. Kawas has extensive experience in the biopharmaceutical sector, having worked at prestigious companies such as Amgen and Genentech. Her contributions to the industry have gained her much recognition; she was included in Forbes’ 30 Under 30 and the Puget Sound Business Journal’s 40 Under 40 lists.
Dr. Kawas has been instrumental in M3 Biotechnology’s progress toward developing new treatments for neurodegenerative diseases. The company’s lead candidate, NurOwn, a small-molecule drug, has seen positive outcomes in early trials for the treatment of Alzheimer’s and other related disorders.
Dr. Kawas is passionate about promoting diversity in science and technology, notably for women and minorities in the STEM fields. She has been a powerful voice at various events and conferences to showcase the importance of such promotion. She has also mentored numerous young women who aspire to pursue careers in STEM fields.
Dr. Kawas has the qualifications to make her an expert in her field. She boasts a Ph.D. in molecular pharmacology from Washington State University and a Bachelor’s degree in pharmacy from Jordan University of Science and Technology. She credits her background in pharmacy for igniting her passion for drug development and discovering new therapies for unmet medical needs.
Leen Kawas has been instrumental in fostering collaboration between academia and industry to advance the development of innovative therapies. She is committed to ensuring that the biopharmaceutical industry stays at the forefront of medical innovation and continues to improve the lives of patients affected by neurodegenerative diseases.
Leen Kawas’ leadership and innovative approach have made her a leading figure in the biopharmaceutical industry. Her dedication to promoting diversity in STEM fields and her tireless efforts to develop new therapies for neurodegenerative diseases make her a role model for aspiring scientists and business leaders.